Is Compounded Semaglutide Still Legal in 2026?

For a couple of years, "compounded semaglutide" was everywhere — cheap GLP-1 weight-loss programs from telehealth sites and med-spas, often a fraction of the price of brand-name Wegovy or Ozempic. That whole market existed because of a drug shortage. In 2025 the shortage officially ended, and the legal ground under mass-compounded semaglutide largely went with it. Here is what changed, what is still allowed, and why the cheap-version era is mostly over.

Why compounded semaglutide was legal in the first place

US law lets compounding pharmacies make a version of an FDA-approved drug under specific circumstances — and one of the biggest is a drug shortage. When the FDA lists a drug as in shortage, both state-licensed 503A pharmacies and larger 503B outsourcing facilities can compound copies to fill the gap, even though those copies are not themselves FDA-approved. Semaglutide spent a long stretch on that shortage list, which is exactly why a sprawling compounded market sprang up around it. The key thing to understand: that legality was always tied to the shortage, not to compounded semaglutide being approved on its own merits. Nor is a compounded vial a generic; we explain the difference in is there a generic Ozempic or Wegovy?.

What changed in 2025

The pivot point was February 21, 2025, when the FDA declared the semaglutide shortage resolved for all dose presentations¹. Once a drug comes off the shortage list, the legal basis for compounding copies of it largely disappears. The FDA gave compounders a short wind-down rather than an overnight cutoff: it said it would not act against 503A pharmacies until April 22, 2025, and against 503B outsourcing facilities until May 22, 2025¹. After those dates, routinely compounding "essentially a copy" of FDA-approved semaglutide is no longer covered by the shortage exception.

An industry group sued to challenge the shortage determination, but in April 2025 a federal court declined to block the FDA, leaving the wind-down in place¹. So as a practical matter, the large-scale, mass-marketed compounded-semaglutide programs lost their legal footing across spring 2025.

What's still allowed in 2026 — and what isn't

This is where the honest nuance lives, because "compounded semaglutide is illegal now" is too blunt.

Traditional, patient-specific 503A compounding still exists. A licensed pharmacy can still compound a medication for an individual patient when there is a genuine clinical reason a commercially available product won't work — for example, a documented allergy to an inactive ingredient, or a needed change in form or strength that the approved product can't provide. What is not allowed is using "compounding" as a cover for cheaply mass-producing copies of an available, approved drug. One practical consequence of that tailoring is that a compounded vial's strength is not standardized the way a pen's is, so the dose you were prescribed and the mark you draw to are two different numbers — the semaglutide dosage chart explains how the two relate. The line is the difference between a tailored clinical need and a price play.

Salt forms were never the workaround they were sold as. Many cheap products used semaglutide sodium or acetate — salt forms — which the FDA has flagged as not the same active ingredient as the approved semaglutide base, and not appropriate for this kind of compounding. A product marketed as "research" semaglutide or a "semaglutide salt" is not a legitimate version of the drug.

The endgame is heading toward a permanent door-close. In April 2026, the FDA proposed to exclude semaglutide (along with tirzepatide and liraglutide) from the 503B "bulk drug substances" list, concluding there is no clinical need for outsourcing facilities to compound it from bulk powder now that the shortage is over². The public comment period was extended once and closed on July 30, 2026⁵. As of October 2026, FDA has not published a final decision, so the proposal is still pending — but if it is finalized, it cements the exclusion and makes clear the shortage-era market is not coming back. If you are on a compounded plan today, that is the date-free fact to plan around: ask your provider what happens to your prescription if the exclusion becomes final.

The safety reason this matters

The safety questions include dosing accuracy and product quality. Compounded semaglutide is not FDA-evaluated for safety, effectiveness, or quality, and the way it was sold created specific hazards. A poison-center case series documented patients self-administering 10-fold overdoses of compounded semaglutide drawn from multi-dose vials — because the vials lacked the safety features of a manufactured pen, the syringes weren't designed for the drug, and the dosing units (milligrams vs units vs milliliters) confused people³. A broader pharmacovigilance analysis of adverse-event reports for compounded GLP-1 products echoed the concern, finding a notable burden of medication errors and adverse events tied to these unstandardized products⁴. The FDA has cited hundreds of adverse-event reports linked to compounded semaglutide as part of its rationale². None of this means every compounded dose is dangerous — but it does mean the cheap version traded away the dose-accuracy and quality controls that come standard with the approved product.

Compounded semaglutide vs Wegovy sets that trade out side by side, with current prices.

One question worth asking before you pay: does the program even say which pharmacy is compounding it? We checked every telehealth provider we track and published who names their pharmacy and who doesn't — most don't. A handful do. Lean Meds lists four compounding pharmacies in its FAQ, each with a street address and a phone number, and calls them state-licensed 503A facilities; Nex Gen Health Rx prints its pharmacy and address in every footer, states the 503A class, and says you may have the prescription filled elsewhere; and Alinwell opens a per-batch certificate of analysis naming the pharmacy that compounded the vial and the accredited laboratory that tested it — it shows the paperwork rather than describing it.

Naming and classifying are separate questions, though: Oria Meds names its dispensing pharmacy in every footer, while the 503A designation sits in a script that renders nowhere a reader can see.

What this means if you're shopping for semaglutide

Practically, in 2026, if you are offered "compounded semaglutide" at a too-good-to-be-true price, treat it skeptically: the broad legal basis for that product ended in 2025, and what remains legitimate is narrow, patient-specific compounding for a real clinical reason — not bulk weight-loss programs. The mainstream, fully legal options are the FDA-approved products: injectable Wegovy and Ozempic, the diabetes pill Rybelsus, and now the oral Wegovy 25 mg pill approved for weight management. They cost more, but they are standardized and overseen.

If cost is the issue — which it usually is — the better path is working the legitimate levers: manufacturer savings programs and coverage. We break those down in Wegovy cost & savings and does insurance cover Wegovy and Ozempic?. For how the brand-name options compare, see Ozempic vs Wegovy, our pillar Semaglutide: how it works, results & side effects, and our best semaglutide guide.

And for where to actually buy the legal brand product online now that the cheap-copy era is over, see the best places to get Wegovy & Ozempic online. If you still want to see who sells it today, our compounded semaglutide provider list shows each program's published price and whether it names its pharmacy.

Because several telehealth brands built their cheap headline on compounded semaglutide, this regulatory shift directly shapes how to read them — see our Hims semaglutide review and Found weight loss review. If you want to see exactly which brands those cheap headlines belong to, we sort every provider we track by published price in the cheapest semaglutide, in price order — read it alongside this page, not instead of it, and alongside our walk-through of what actually happens between the intake form and the box, where the compounding question is step three.

The narrowing has not stopped anyone advertising: EverSlim quotes one figure covering the visit, the prescription and delivery and names the pharmacies that fill it, and Telos Rx sells compounded peptides alongside its GLP-1 line. Neither is illegitimate on its face; both are worth reading with this page's timeline in mind.

Nolu names no medical director, prescriber or pharmacy anywhere on its site, and bills its published figure every four weeks rather than by the calendar month, and FORM by GBY names no pharmacy either, describing it only as "US licensed pharmacies", while He & She MD publishes the name, street address and phone number of the pharmacy that fills its prescriptions.

HumeCare names no pharmacy at all and describes itself as a platform whose prescribing clinicians are a separate entity, so ask who prescribes and which pharmacy dispenses before paying. EdgeRx is the rarer counter-example: it names its compounding pharmacy, Strive Pharmacy, outright on its own site, which is closer to the disclosure a shopper should be looking for than most of this field manages.

There is also a version of this where the pharmacy disclosure is excellent and everything a shopper needs is still missing: Lighter You names four dispensing pharmacies with street addresses and never once states a dose, a route, or whether its semaglutide is compounded or branded — you can look up who might fill it, but not what it is.

Rarer still, one practice publishes all four of the compounding pharmacies it works with, with a phone number beside each — which means the question this page keeps asking, who actually mixed the drug in the vial, is one you can put to the pharmacy yourself before you pay.

Zealthy is a sharper example of why this timeline matters: the FDA has sent its parent company two separate warning letters, in September 2025 and again in February 2026, specifically over how it marketed compounded semaglutide and tirzepatide after the shortage exemption this page describes had already ended.

Disclosure varies wildly on this point. SnagRx names all four of its partner pharmacies in its Terms, with street addresses and phone numbers, which is more than most compounded sellers put in writing. Trinity Meds goes as far, naming four 503A pharmacies with street addresses in its FAQ. altRx lists the four state-licensed 503A pharmacies in its network in its own FAQ, each with an address, so you can look up who compounds your vial before you order. At the other end, TrimRx sells its main compounded product under the label "GLP-1" without naming the drug at all, so the first question there is what is actually in the vial. WeightCare says only that an accredited U.S. pharmacy fills its prescriptions, without naming it, while Pomegranate Health lists six partner pharmacies on its pricing page but says in its terms that it cannot guarantee which one fills an order.